Generic RAVICTI® Options – Living Updates
FDA Approval & Endo Announcement
October 20, 2025, Endo, a wholly-owned subsidiary of Mallinckrodt plc, announced the launch of a generic version of RAVICTI® (1.1 gm/mL oral liquid). Availability and pricing details not yet provided. Read the full announcement.
Lupin Launches Authorized Generic Version of Ravicti® in the United States
Mumbai, Naples, October 24, 2025: Global pharma major Lupin Limited (Lupin) today announced the launch of an authorized generic version of Ravicti® (Glycerol Phenylbutyrate) Oral Liquid, 1.1g/mL, in the United States. Read the full announcement. Based on current information, Lupin is expected to enter the market following the 180-day exclusivity period for Endo’s product.
Lupin Savings Program
Philanthropic Initiative
In addition, as previously announced at the 2025 NUCDF Family Conference, a separate, fully funded philanthropic initiative to develop an affordable and accessible generic option is also underway.
NUCDF recognizes that there is uncertainty regarding generic glycerol phenylbutyrate. We have heard the concerns expressed by the patient community regarding the timing and availability of generic options and what impact that may have on patient access to these lifesaving medications.
NUCDF Support & Updates
In alignment with our mission, NUCDF remains dedicated to supporting all initiatives that enhance access. Our goal is to ensure that patients will have consistent and affordable access to this essential medication. We will continue to seek and share the latest information on this topic as it becomes available.
The community reports that switching from Ravicti® to the generic version offered by Endo has resulted in a cost reduction of approximately 10–15%.
